Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6843224 | 0.91 | LMNA (0.50) | MEN1KMT2ANPC1RAB9ALMNA | |
| SCHEMBL6843418 | 0.89 | SRD5A2 (0.45) | MEN1KMT2APIM1NPC1RAB9A | |
| SCHEMBL6844736 | 0.89 | NR4A2 (0.45) | RXRARXRBMEN1KMT2APIM1 | |
| SCHEMBL6843050 | 0.89 | MAPT (0.46) | MEN1KMT2APIM1NPC1RAB9A | |
| SCHEMBL6844631 | 0.89 | RXRA (0.45) | RXRARXRBMEN1KMT2APIM1 | |
| SCHEMBL7104741 | 0.88 | KMT2A (0.43) | MEN1KMT2APIM1NPC1RAB9A | |
| SCHEMBL6844668 | 0.87 | NPC1 (0.49) | RXRARXRBMEN1KMT2ANPC1 | |
| SCHEMBL6843022 | 0.86 | SRD5A2 (0.48) | RXRARXRBMEN1KMT2APIM1 | |
| SCHEMBL6838251 | 0.86 | ALDH1A1 (0.52) | MEN1KMT2APIM1NPC1RAB9A | |
| SCHEMBL6845360 | 0.86 | MEN1 (0.39) | MEN1KMT2APIM1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | RXRA 2850/4885RXRB 2848/4885MEN1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.